HeartSciences (NASDAQ:HSCS – Get Free Report) and Movano (NASDAQ:MOVE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Earnings and Valuation
This table compares HeartSciences and Movano”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| HeartSciences | N/A | N/A | -$8.77 million | ($6.88) | -0.41 |
| Movano | $1.01 million | 6.69 | -$23.73 million | ($10.83) | -0.75 |
Volatility & Risk
HeartSciences has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500. Comparatively, Movano has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for HeartSciences and Movano, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| HeartSciences | 1 | 0 | 1 | 0 | 2.00 |
| Movano | 1 | 0 | 0 | 0 | 1.00 |
HeartSciences presently has a consensus target price of $9.20, suggesting a potential upside of 222.81%. Given HeartSciences’ stronger consensus rating and higher possible upside, research analysts clearly believe HeartSciences is more favorable than Movano.
Profitability
This table compares HeartSciences and Movano’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| HeartSciences | N/A | -388.12% | -161.65% |
| Movano | -3,409.60% | -647.91% | -225.03% |
Insider & Institutional Ownership
17.2% of HeartSciences shares are held by institutional investors. Comparatively, 16.6% of Movano shares are held by institutional investors. 1.8% of HeartSciences shares are held by insiders. Comparatively, 10.4% of Movano shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
HeartSciences beats Movano on 11 of the 13 factors compared between the two stocks.
About HeartSciences
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
About Movano
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
Receive News & Ratings for HeartSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartSciences and related companies with MarketBeat.com's FREE daily email newsletter.
